Moderna, Inc. (MRNA) has agreed to pay $950 million upfront and up to an additional $1.3 billion under a $2.25 billion global settlement with Genevant Sciences, a subsidiary of Roivant Sciences Ltd. (ROIV), and Arbutus Biopharma Corporation (ABUS) to resolve patent litigation related to lipid nanoparticle (LNP) delivery technology used in its COVID-19 vaccine.
Under the agreement, Moderna will make a $950 million payment in July 2026. An additional $1.3 billion payment is contingent on a favorable appellate ruling regarding Section 1498 of U.S. law, which Moderna had argued shields certain government-contracted sales from patent liability.
As part of the settlement, Genevant will grant Moderna a global non-exclusive license to its LNP delivery technology for infectious disease applications and a covenant not to sue on certain patents, ending all related litigation tied to Moderna's COVID-19 vaccine.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.